Silence Therapeutics (SLN) Non-Current Deferred Tax Liability (2018 - 2020)
Silence Therapeutics (SLN) posted Non-Current Deferred Tax Liability of $33011.3 for Q4 2020, up 6.98% sequentially from $30857.4 in Q4 2019, and up 6.98% YoY from $30857.4 in Q1 2020.
Silence Therapeutics (SLN) Non-Current Deferred Tax Liability (2018 - 2020) Analysis & Trends
Silence Therapeutics has reported Non-Current Deferred Tax Liability for 3 years, with the latest figure at $33011.3 in Q4 2020.
- Quarterly Non-Current Deferred Tax Liability rose 6.98% year-over-year to $33011.3 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $33011.3 (up 6.98% YoY) and the FY2020 annual result came in at $32103.7, up 4.76% from the prior year.
- Non-Current Deferred Tax Liability grew to $33011.3 in Q4 2020 per SLN's latest filing, from $30857.4 in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $33011.3 in Q4 2020 and troughed at $16728.0 in Q4 2018.
- A 3-year average of $26865.5 and a median of $30857.4 in 2019 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2019 and 2020: Non-Current Deferred Tax Liability jumped 84.47% in 2019, then increased 6.98% in 2020.
- Over 3 years, Non-Current Deferred Tax Liability stood at $16728.0 in 2018, then soared by 84.47% to $30857.4 in 2019, then climbed by 6.98% to $33011.3 in 2020.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $33011.3, $30857.4, and $16728.0 for Q4 2020, Q4 2019, and Q4 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Silence Therapeutics | 648.22 Mn | 576.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 33,011.28 |
| Dec 31, 2020 | 33,011.28 |
| Dec 31, 2019 | 30,857.40 |
| Dec 31, 2019 | 30,857.40 |
| Dec 31, 2018 | 16,727.97 |
| Dec 31, 2018 | 16,727.97 |